Summary
To assess the practical prognostic value of c-erbB2, we performed a study on 942 invasive ductal carcinomas treated with primary surgery between 1980 and 1986 in our center. We evaluated its expression by immunohistochemistry in paraffin-embedded tissue using a polyclonal antipeptide antibody. Of 942 tumors, 229 (24%) showed a positive membrane staining. We observed a significant association between c-erbB2 and Scarff-Bloom-Richardson grading (p < 0.0001) and a negative correlation between c-erbB2 and both estrogen and progesterone receptors (p < 0.0001). In our analysis, with respect to overall survival (OS), relapse-free survival (RFS), and metastasis-free survival (MFS), c-erbB2 was statistically significant (p ≤ 0.0001) for the whole group and the node-positive subgroup. In multivariate analysis, c-erbB2 appeared to be an independant variable for RFS and MFS in the node-negative group. However, in our hands, c-erbB2 had a poor prognostic value in comparison with the classical prognostic variables such as histological grade, nodal status (N), hormonal receptor status (estrogen and progesterone receptors), and tumor size, and it did not supersede the classical parameters.
Article PDF
Avoid common mistakes on your manuscript.
References
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177–182, 1987
Guerin M, Galillot M, Mathieu MC, Travagli JP, Spielmann M, Andrieu N, Riou G: Structure and expression of c-erbB2 and EGF receptor genes in inflammatory and non inflammatory breast cancer: Prognostic significance. Int J Cancer 43: 201–208, 1989
May E, Mouriesse H, May-Levin F, Qian JF, May P, Delarue JC: Human breast cancer: identification of populations with a high risk of early relapse in relation to both oestrogen receptor status and c-erbB-2 overexpression. Br J Cancer 62: 430–435, 1990
Wolber RA, Dupuis BA, Wick MR: Expression of c-erbB2 oncoprotein in mammary and extramammary Paget's disease. Am J Clin Pathol 96: 243–247, 1991
Gullick WJ, Tuzi NL, Kumar S, Paterson H, Quirke P, Venter DJ: c-erbB2 and c-myc genes and their expression in normal tissues and in human breast cancer. Cancer Cells 7: 393–398, 1989
Venter DJ, Tuzi NL, Kumar S, Gullick WJ: Overexpression of the c-erbB2 oncoprotein in human breast carcinomas: Immunohistological assessment correlates with gene amplification. Lancet ii: 69–71, 1987
Parkes HC, Lillycrop K, Howell A, Craig RK: c-erbB2 mRNA expression in human breast tumours: comparison with c-erbB2 DNA amplification and correlation with prognosis. Br J Cancer 61: 39–45, 1990
Tsutsumi Y, Naber SP, DeLellis RA, Wolfe HJ, Marks PJ, McKenzie SJ, Yin S: Neu oncogene protein and epidermal growth factor receptor are independently expressed in benign and malignant breast tissues. Hum Pathol 21: 750–758, 1990
Dati C, Muraca R, Tazartes O, Antoniotti S, Perroteau I, Giai M, Cortese P, Sismondi P, Saglio G, de Bortoli M: c-erbB-2 and ras expression levels in breast cancer are correlated and show a co-operative association with unfavorable clinical outcome. Int J Cancer 47: 833–838, 1991
Soubeyran I, Coindre JM, Wafflart J, Bonichon F, de Mascarel I, Trojani M, Durand M, Avril A: Immunohistochemical determination of PS2 in invasive breast carcinomas: a study on 942 cases. Breast Cancer Res Treat 34: 119–128, 1995
Bloom HJG, Richardson WW: Histological grading and prognosis in breast cancer. Br J Cancer 11: 359, 1957
Børresen AL, Ottestad L, Gaustad A, Andersen TI, Heikkilä R, Jahnsen T, Tveit KM, Nesland JM: Amplification and protein over-expression of the neu/HER-2/c-erbB-2 protooncogene in human breast carcinomas: relationship to loss of gene sequences on chromosome 17, family history and prognosis. Br J Cancer 62: 585–590, 1990
Kallioniemi OP, Holli K, Visakorpi T, Koivula T, Helin HH, Isola JJ: Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 49: 650–655, 1991
Press MF, Schwartz AM: Her-2/neu and breast cancer. In: Prognostic markers in breast cancer: laboratory analysis of breast biopsies. USCAP 83rd Annual Meeting San Francisco 1994 (Abstract)
Rilke F, Colnaghi MI, Cascinelli N, Andreola S, Baldini MT, Bufalino R, Della Porta G, Ménard S, Pierotti MA, Testori A: Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer 49: 44–49, 1991
Ro J, El-Naggar A, Ro JY, Blick M, Frye D, Fraschini G, Fritsche H, Hortobagyi G: c-erbB-2 amplification in nodenegative human breast cancer. Cancer Res 49: 6941–6944, 1989
Seshadri R, Matthews C, Dobrovic A, Horsfall DJ: The significance of oncogene amplification in primary breast cancer. Int J Cancer 43: 270–272, 1989
Toikkhanen S, Helin H, Isola J, Joensuu H: Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol 10: 1044–1048, 1992
Van de Vijver MJ, Mooi WJ, Peterse JL, Nusse R: Amplification and over-expression of the neu oncogene in human breast carcinomas. Eur J Surg Oncol 14: 111–114, 1988
Varley JM, Swallow JE, Brammar WJ, Whittaker JL, Walker RA: Alterations to either c-erbB-2 (neu) or c-myc protooncogenes in breast carcinomas correlate with poor shortterm prognosis. Oncogene 1: 423–430, 1987
Winstanley J, Cooke T, Murray GD, Platt-Higgins A, George WD, Holt S, Myskov M, Spedding A, Barraclough BR, Rudland PS: The long term prognostic significance of c-erbB-2 in primary breast cancer. Br J Cancer 63: 447–450, 1991
Zhou D, Battifora H, Yokota J, Yamamoto T, Cline MJ: Association of multiple copies of the c-erbB-2 oncogene with spread of breast cancer. Cancer Res 47: 6123–6125, 1987
Berger MS, Locher GW, Saurer S, Gullick WJ, Waterfield MD, Groner B, Hynes NE: Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 48: 1238–1243, 1988
Gullick WJ, Love SB, Wright C, Barnes DM, Gusterson B, Harris AL, Altman DG: c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 63: 434–438, 1991
Iglehart JD, Kraus MH, Langton BC, Huper G, Kerns BJ, Marks JR: Increased erbB-2 gene copies and expression in multiple stages of breast cancer. Cancer Res 50: 6701–6707, 1990
Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL: HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 7: 1120–1128, 1989
Wright C, Angus B, Nicholson S, Sainsbury JRC, Cairns J, Gullick WJ, Kelly P, Harris AL, Horne CHW: Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res 49: 2087–2090, 1989
Barnes DM: Breast cancer and a proto-oncogene. c-erB-2 is a reliable prognostic marker. Br Med J 299: 1061, 1989
Lovekin C, Ellis IO, Locker A, Robertson JFR, Bell J, Nicholson R, Gullick WJ, Elston CW, Blamey RW: c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 63: 439–443, 1991
McCann AH, Dervan PA, O'Regan M, Codd MB, Gullick WJ, Tobin BMJ, Carney DN: Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. Cancer Res 51: 3296–3303, 1991
Tsuda H, Hirohashi S, Shimosato Y, Hirota T, Tsugane S, Watanabe S, Terada M, Yamamoto H: Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma. Cancer 65: 1794–1800, 1990
De Potter CR, Beghin C, Makar AP, Vandekerckhove D, Roels HJ: The neu-oncogene protein as a predictive factor for haematogenous metastases in breast cancer patients. Int J Cancer 45: 55–58, 1990
Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Sâve-Söderborgh J, Anbazhagan R, Styles J, Rudenstam CM, Golough R, Reed R, Martinez-Tello F, Tiltman A, Torhorst J, Grigolato P, Bettelheim R, Neville AM, Bürki K, Castiglione M, Collins J, Lindtner J, Senn HJ, for the International (Ludwig) Breast Cancer Study Group: Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 10: 1049–1056, 1992
Heintz NH, Leslie KO, Rogers LA, Howard PL: Amplification of the c-erbB-2 oncogene and prognosis of breast adenocarcinoma. Arch Pathol Lab Med 114: 160–163, 1990
Le Roy X, Escot C, Brouillet JP, Theillet C, Maudelonde T, Simony-Lafontaine J, Pujol H, Rochefort H: Decrease of c-erbB-2 and c-myc RNA levels in tamoxifen-treated breast cancer. Oncogene 6: 431–437, 1991
O'Reilly SM, Barnes DM, Camplejohn RS, Bartkova J, Gregory WM, Richards MA: The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer. Br J Cancer 63: 444–446, 1991
Querzoli P, Marchetti E, Fabris G, Marzola A, Ferretti S, Iacobelli S, Hazan R, King CR, Nenci I: Immunohistochemical expression of c-erbB-2 in human breast cancer by monoclonal antibody: correlation with lymph node and ER status. Tumori 76: 461–464, 1990
Perren TJ: c-erbB-2 oncogene as a prognostic marker in breast cancer. Br J Cancer 63: 328–332, 1991
Thor AD, Schwartz LH, Koerner FC, Edgerton SM, Skates SJ, Yin S, McKenzie SJ, Panicali DL, Marks PJ, Fingert HJ, Wood WC: Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up. Cancer Res 49: 7147–7152, 1989
Tsuda H, Hirohashi S, Shimosato Y, Hirota T, Tsugane S, Yamamoto H, Miyajima N, Toyoshima K, Yamamoto T, Yokota J, Yoshida T, Sakamoto H, Terada M, Sugimura T: Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1. Cancer Res 49: 3104–3108, 1989
Dykins R, Corbett IP, Henry JA, Wright C, Yuan J, Hennessy C, Lennard TJW, Angus B, Horne CHW: Long-term survival in breast cancer related to overexpression of the c-erbB-2 oncoprotein: an immunohistochemical study using monoclonal antibody NCL-CB11. J Pathol 163: 105–110, 1991
Richner J, Gerber HA, Locher GW, Goldhirsch A, Gelber RD, Gullick WJ, Berger MS, Groner B, Hynes NE: c-erbB-2 protein expression in node negative breast cancer. Ann Oncol 1: 263–268, 1990
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Quénel, N., Wafflart, J., Bonichon, F. et al. The prognostic value of c-erbB2 in primary breast carcinomas: A study on 942 cases. Breast Cancer Res Tr 35, 283–291 (1995). https://doi.org/10.1007/BF00665980
Issue Date:
DOI: https://doi.org/10.1007/BF00665980